JP2017158561A5 - - Google Patents

Download PDF

Info

Publication number: JP2017158561A5
Authority: JP; Japan
Prior art keywords: inflammatory; seq; composition according; composition; amino acid
Prior art date: 2017-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2017077422A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017158561A (ja

JP6514259B2 (ja

Filing date

2017-04-10

Publication date

2018-11-22

2012-07-20 Priority claimed from KR1020120079096A external-priority patent/KR20140012385A/ko

2012-08-14 Priority claimed from KR1020120089162A external-priority patent/KR20140022698A/ko

2012-08-14 Priority claimed from KR1020120089167A external-priority patent/KR20140022699A/ko

2017-04-10 Application filed filed Critical

2017-09-14 Publication of JP2017158561A publication Critical patent/JP2017158561A/ja

2018-11-22 Publication of JP2017158561A5 publication Critical patent/JP2017158561A5/ja

2019-05-15 Application granted granted Critical

2019-05-15 Publication of JP6514259B2 publication Critical patent/JP6514259B2/ja

Status Active legal-status Critical Current

2033-03-15 Anticipated expiration legal-status Critical

Links

108090000765 processed proteins & peptides Proteins 0.000 claims description 3
239000000203 mixture Substances 0.000 claims 7
230000003110 anti-inflammatory effect Effects 0.000 claims 4
125000003275 alpha amino acid group Chemical group 0.000 claims 3
208000027866 inflammatory disease Diseases 0.000 claims 2
230000002265 prevention Effects 0.000 claims 2
201000004624 Dermatitis Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
239000002537 cosmetic Substances 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1

JP2017077422A 2012-07-20 2017-04-10 抗炎症活性を有するペプチド、及びそれを含む組成物 Active JP6514259B2 (ja)

Applications Claiming Priority (12)

Application Number	Priority Date	Filing Date	Title
KR10-2012-0079096		2012-07-20
KR1020120079096A KR20140012385A (ko)	2012-07-20	2012-07-20	항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물
KR10-2012-0089167		2012-08-14
KR10-2012-0089161		2012-08-14
KR20120089161		2012-08-14
KR10-2012-0089162		2012-08-14
KR1020120089162A KR20140022698A (ko)	2012-08-14	2012-08-14	텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR1020120089167A KR20140022699A (ko)	2012-08-14	2012-08-14	텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR20120104144		2012-09-19
KR10-2012-0104207		2012-09-19
KR20120104207		2012-09-19
KR10-2012-0104144		2012-09-19

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2015521997A Division JP6352911B2 (ja)	2012-07-20	2013-03-15	抗炎症活性を有するペプチド、及びそれを含む組成物

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019075635A Division JP6788062B2 (ja)	2012-07-20	2019-04-11	抗炎症活性を有するペプチド、及びそれを含む組成物

Publications (3)

Publication Number	Publication Date
JP2017158561A JP2017158561A (ja)	2017-09-14
JP2017158561A5 true JP2017158561A5 (2)	2018-11-22
JP6514259B2 JP6514259B2 (ja)	2019-05-15

Family

ID=47882177

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
JP2015521997A Active JP6352911B2 (ja)	2012-07-20	2013-03-15	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2017077422A Active JP6514259B2 (ja)	2012-07-20	2017-04-10	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2019075635A Active JP6788062B2 (ja)	2012-07-20	2019-04-11	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2020181780A Active JP7128246B2 (ja)	2012-07-20	2020-10-29	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2022130519A Active JP7440581B2 (ja)	2012-07-20	2022-08-18	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2024021407A Active JP7741218B2 (ja)	2012-07-20	2024-02-15	抗炎症活性を有するペプチド、及びそれを含む組成物

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
JP2015521997A Active JP6352911B2 (ja)	2012-07-20	2013-03-15	抗炎症活性を有するペプチド、及びそれを含む組成物

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
JP2019075635A Active JP6788062B2 (ja)	2012-07-20	2019-04-11	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2020181780A Active JP7128246B2 (ja)	2012-07-20	2020-10-29	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2022130519A Active JP7440581B2 (ja)	2012-07-20	2022-08-18	抗炎症活性を有するペプチド、及びそれを含む組成物
JP2024021407A Active JP7741218B2 (ja)	2012-07-20	2024-02-15	抗炎症活性を有するペプチド、及びそれを含む組成物

Country Status (8)

Country	Link
US (6)	US20150125438A1 (2)
EP (3)	EP2875042B1 (2)
JP (6)	JP6352911B2 (2)
KR (2)	KR20150031413A (2)
CN (3)	CN117551631A (2)
ES (3)	ES2693321T3 (2)
TW (6)	TWI700290B (2)
WO (1)	WO2014012683A1 (2)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9320058D0 (en)	1993-09-29	1993-11-17	Gillette Co	Savety razors
ES2691070T3 (es)	2012-05-11	2018-11-23	Kael-Gemvax Co.,Ltd	Péptidos antiinflamatorios y composición que comprende los mismos
ES2981865T3 (es)	2012-07-11	2024-10-10	Gemvax & Kael Co Ltd	Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en)	2012-07-20	2015-05-07	Sang Jae Kim	Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616531B (zh)	2012-09-19	2018-03-01	傑姆維克斯＆凱爾有限公司	穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
TWI678374B (zh)	2012-09-19	2019-12-01	韓商傑姆維克斯＆凱爾有限公司	穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
SG11201507306VA (en)	2013-03-15	2015-10-29	Promega Corp	Activation of bioluminescence by structural complementation
RU2677277C2 (ru)	2013-06-07	2019-01-16	Джемвакс Энд Каэл Ко., Лтд.	Биологические маркеры, которые могут быть использованы в иммунотерапии рака
TWI539960B (zh)	2013-06-21	2016-07-01	凱爾傑姆維克斯有限公司	激素分泌調節劑、包括其的組成物以及其用途
US9757473B2 (en) *	2013-07-12	2017-09-12	Gemvax & Kael Co., Ltd.	Cell-penetrating peptide and conjugate comprising same
EP3072519B1 (en)	2013-11-22	2020-08-19	Gemvax & Kael Co., Ltd.	Peptide having angiogenesis inhibitory activity and composition containing same
ES2809251T3 (es)	2013-12-17	2021-03-03	Gemvax & Kael Co Ltd	Composición para tratar cáncer de próstata
JP6420459B2 (ja) *	2014-04-11	2018-11-07	ジェムバックスアンドカエルカンパニー，リミティド	線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en)	2014-04-30	2020-05-26	Gemvax & Kael Co., Ltd.	Composition for organ, tissue, or cell transplantation, kit, and transplantation method
EP3193906B1 (en) *	2014-09-18	2020-11-11	The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin	Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
KR102413243B1 (ko)	2014-12-23	2022-06-27	주식회사 젬백스앤카엘	안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko)	2015-02-27	2024-02-14	주식회사 젬백스앤카엘	청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
KR101662438B1 (ko) *	2015-04-07	2016-10-04	가톨릭대학교 산학협력단	X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
KR101734529B1 (ko)	2015-05-08	2017-05-11	건국대학교 산학협력단	패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
WO2016190660A1 (ko)	2015-05-26	2016-12-01	주식회사 젬백스앤카엘	신규 펩티드 및 이를 포함한 조성물
EP3318265B1 (en)	2015-07-02	2021-08-18	Gemvax & Kael Co., Ltd.	Peptide having anti-viral effect and composition containing same
EP3341389B1 (en) *	2015-08-28	2021-10-06	The Medical College of Wisconsin, Inc.	Peptide inhibitors of telomerase translocation and therapeutic uses thereof
WO2017044885A1 (en) *	2015-09-09	2017-03-16	uBiome, Inc.	Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
EP4272829A3 (en) *	2016-04-07	2024-01-17	Gemvax & Kael Co., Ltd.	Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
KR101831888B1 (ko) *	2016-04-15	2018-04-16	(주)케어젠	항염증 활성을 갖는 펩타이드 및 이의 용도
KR101887577B1 (ko) *	2016-10-19	2018-09-10	(주)케어젠	항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR102490489B1 (ko) *	2016-12-22	2023-01-19	유니베르시테 드 몽펠리에	신규한 스테이플화 펩티드 및 이의 용도
JP6601848B2 (ja) *	2017-08-21	2019-11-06	株式会社大一商会	遊技機
JP6601849B2 (ja) *	2017-08-21	2019-11-06	株式会社大一商会	遊技機
KR102092843B1 (ko) *	2018-08-30	2020-03-24	충남대학교 산학협력단	암 예방 또는 치료용 펩타이드 및 이의 용도
KR102274658B1 (ko) *	2018-11-16	2021-07-09	주식회사 카인사이언스	염증성 피부질환 치료용 펩타이드 및 이의 용도
KR102032945B1 (ko) *	2018-12-03	2019-10-16	순천대학교 산학협력단	항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
KR102146937B1 (ko) *	2018-12-11	2020-08-21	대한민국	왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물
KR102266613B1 (ko) *	2020-09-21	2021-06-18	자안바이오 주식회사	항염증 활성을 갖는 신규한 펩티드 및 이의 용도
WO2022167656A1 (en) *	2021-02-08	2022-08-11	Bacoba Ag	Treatment of skin disorders
KR20230156265A (ko) *	2022-05-03	2023-11-14	한국생명공학연구원	신규 펩타이드 및 이의 항염 및 재생 용도
KR102827929B1 (ko) *	2023-01-26	2025-07-09	㈜에빅스젠	신규한 뇌 질환 치료제 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1523965A (en) *	1976-03-19	1978-09-06	Ici Ltd	Pharmaceutical compositions containing steroids
DE4330664A1 (de) *	1993-09-10	1995-03-16	Beiersdorf Ag	Verwendungen von Pflanzenölen
RO117328B1 (ro) *	1994-07-07	2002-01-30	Geron Corp	Componenta rna a telomerazei de mamifere, plasmida recombinanta, de exprimare a acesteia, si metoda pentru detectarea prezentei unei stari neoplazice
SI0912558T1 (en) *	1996-06-25	2003-10-31	Pfizer Inc.	Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
US6610839B1 (en) *	1997-08-14	2003-08-26	Geron Corporation	Promoter for telomerase reverse transcriptase
IL129222A0 (en) *	1996-10-01	2000-02-17	Geron Corp	Telomerase reverse transcriptase
KR100581990B1 (ko) *	1997-07-01	2006-05-23	캄비아 바이오시스템즈 엘엘씨	척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
US7030211B1 (en) *	1998-07-08	2006-04-18	Gemvax As	Antigenic peptides derived from telomerase
EP1423140A2 (en) *	2001-07-31	2004-06-02	Karl Petter Söderström	Compositions and methods for modulation of immune responses
US20060127894A1 (en) *	2001-08-08	2006-06-15	Incyte Corporation	Protein associated with cell growth, differentiation, and death
US8492438B2 (en) *	2002-04-26	2013-07-23	Asan Laboratories Company (Cayman), Limited	Treatment skin disorders
WO2004099377A2 (en) *	2003-05-01	2004-11-18	Musc Foundation For Research Development	An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
CN101011571A (zh) *	2006-03-13	2007-08-08	上海交通大学医学院	GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用
WO2008035350A1 (en) *	2006-09-21	2008-03-27	Vaxil Biotherapeutics Ltd.	Antigen specific multi epitope vaccines
CA2664168A1 (en) *	2006-10-12	2008-04-17	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
BRPI0811651A2 (pt)	2007-05-18	2014-11-11	Inhibox Ltd	Composto, composição farmacêutica, métodos para preparar uma composição farmacêutica, para tratar uma doença, distúrbio ou condição, para inibir a tace em uma célula, in vitro ou in vivo, e de regular (por exemplo, inibir) a liberação da citocina (por exemplo, a liberação da tnf-alfa) em uma célula, in vitro ou in vivo, uso de um composto, e, kit
US8362209B2 (en)	2007-08-23	2013-01-29	University Of Medicine And Dentistry Of New Jersey	Telomerase reverse transcriptase variant
GB2455539B (en)	2007-12-12	2012-01-18	Cambridge Entpr Ltd	Anti-inflammatory compositions and combinations
PL2310044T3 (pl) *	2008-06-16	2017-04-28	Mediolanum Farmaceutici S.P.A.	Immunoterapia przeciwnowotworowa
US8252282B2 (en) *	2008-06-19	2012-08-28	University Of Medicine & Dentistry Of New Jersey	Nuclear telomerase reverse transcriptase variant
US20110183925A1 (en)	2008-09-22	2011-07-28	Nisshin Pharma Inc.	Anti-inflammatory peptide
EP2337795A2 (en)	2008-10-01	2011-06-29	Dako Denmark A/S	Mhc multimers in cancer vaccines and immune monitoring
PL2536830T3 (pl) *	2010-02-16	2020-02-28	Ultimovacs As	Polipeptydy
KR101284772B1 (ko)	2011-05-24	2013-07-17	정종문	항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko)	2011-05-31	2012-12-11	주식회사 바이오포트코리아	아스타잔틴을 포함하는 항염증제
ES2691070T3 (es)	2012-05-11	2018-11-23	Kael-Gemvax Co.,Ltd	Péptidos antiinflamatorios y composición que comprende los mismos
US20150125438A1 (en)	2012-07-20	2015-05-07	Sang Jae Kim	Anti-Inflammatory Peptides and Composition Comprising the Same
TWI678374B (zh)	2012-09-19	2019-12-01	韓商傑姆維克斯＆凱爾有限公司	穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
US9631184B2 (en)	2012-09-19	2017-04-25	Gemvax & Kael Co., Ltd.	Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
TWI616531B (zh)	2012-09-19	2018-03-01	傑姆維克斯＆凱爾有限公司	穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
RU2677277C2 (ru) *	2013-06-07	2019-01-16	Джемвакс Энд Каэл Ко., Лтд.	Биологические маркеры, которые могут быть использованы в иммунотерапии рака
US9757473B2 (en)	2013-07-12	2017-09-12	Gemvax & Kael Co., Ltd.	Cell-penetrating peptide and conjugate comprising same
WO2016190660A1 (ko)	2015-05-26	2016-12-01	주식회사 젬백스앤카엘	신규 펩티드 및 이를 포함한 조성물
TW201718028A (zh)	2015-10-13	2017-06-01	賽米克Ｉｐ有限責任公司	Ve-鈣黏蛋白結合性生物結合物

2013
- 2013-03-05 US US14/400,322 patent/US20150125438A1/en not_active Abandoned
- 2013-03-15 EP EP13709221.9A patent/EP2875042B1/en active Active
- 2013-03-15 KR KR1020147034319A patent/KR20150031413A/ko not_active Ceased
- 2013-03-15 EP EP21162575.1A patent/EP3896078B1/en active Active
- 2013-03-15 ES ES13709221T patent/ES2693321T3/es active Active
- 2013-03-15 CN CN202311502816.XA patent/CN117551631A/zh active Pending
- 2013-03-15 CN CN201910110866.0A patent/CN109777791B/zh active Active
- 2013-03-15 KR KR1020207019525A patent/KR102302392B1/ko active Active
- 2013-03-15 CN CN201380038045.1A patent/CN104470947B/zh active Active
- 2013-03-15 JP JP2015521997A patent/JP6352911B2/ja active Active
- 2013-03-15 ES ES18187426T patent/ES2871899T3/es active Active
- 2013-03-15 ES ES21162575T patent/ES3055196T3/es active Active
- 2013-03-15 WO PCT/EP2013/055326 patent/WO2014012683A1/en not_active Ceased
- 2013-03-15 EP EP18187426.4A patent/EP3428182B1/en active Active
- 2013-05-01 TW TW108101145A patent/TWI700290B/zh active
- 2013-05-01 TW TW109115548A patent/TWI779287B/zh active
- 2013-05-01 TW TW111118818A patent/TWI836435B/zh active
- 2013-05-01 TW TW102115615A patent/TWI658141B/zh active
- 2013-05-01 TW TW106121753A patent/TWI647311B/zh active
- 2013-05-01 TW TW113100053A patent/TW202417473A/zh unknown
2017
- 2017-04-05 US US15/479,746 patent/US20170275603A1/en not_active Abandoned
- 2017-04-10 JP JP2017077422A patent/JP6514259B2/ja active Active
2019
- 2019-04-11 JP JP2019075635A patent/JP6788062B2/ja active Active
2020
- 2020-01-17 US US16/746,018 patent/US20200140832A1/en not_active Abandoned
- 2020-03-13 US US16/818,001 patent/US11098294B2/en active Active
- 2020-10-29 JP JP2020181780A patent/JP7128246B2/ja active Active
2021
- 2021-07-30 US US17/389,671 patent/US11905536B2/en active Active
2022
- 2022-08-18 JP JP2022130519A patent/JP7440581B2/ja active Active
2024
- 2024-01-12 US US18/411,838 patent/US20240158768A1/en active Pending
- 2024-02-15 JP JP2024021407A patent/JP7741218B2/ja active Active

Publication	Publication Date	Title
JP2017158561A5 (2)	2018-11-22
Cheng et al.	2009	TGF-β1 gene silencing for treating liver fibrosis
MX393855B (es)	2025-03-21	Terapia de combinación que comprende un inhibidor de raf y trametinib
RU2017101705A (ru)	2018-07-27	Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii
JP2015517488A5 (2)	2016-06-30
JPWO2019156137A5 (2)	2022-01-31
JP2018509388A5 (2)	2019-03-07
JP2015178529A5 (2)	2016-06-09
JP2014515763A5 (2)	2015-06-25
JP2017503820A5 (2)	2018-03-01
JP2016506416A5 (2)	2017-02-16
EA201992607A1 (ru)	2020-06-29	Твердые формы берберина урсодезоксихолата, их композиции и способы
RU2020126034A (ru)	2020-09-02	Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
JPWO2019107530A5 (2)	2022-02-14
MY201105A (en)	2024-02-06	Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN110114083A (zh)	2019-08-09	一种预防和治疗脂肪肝的方法
JP2019533722A5 (2)	2020-10-01
RU2016108808A (ru)	2017-09-14	Терапевтическое применение vegf-c и ccbe1
Liu et al.	2022	Chrysin ameliorates influenza virus infection in the upper airways by repressing virus-induced cell cycle arrest and mitochondria-dependent apoptosis
CY1125769T1 (el)	2026-02-25	Φαρμακευτικοι συνδυασμοι που περιεχουν εναν αναστολεα αποακετυλασης ιστονων και εναν αναστολεα bcl-2 και μεθοδοι χρησης αυτων
MY178445A (en)	2020-10-13	Novel antibody binding to tfpi and composition comprising the same
EP4225382A4 (en)	2025-04-23	ADMINISTRATION OF THERAPEUTIC ADENO-ASSOCIATED VIRUS FUKKUTIN-ASSOCIATED PROTEIN (FKRP) FOR THE TREATMENT OF DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21
JP2019531293A5 (2)	2020-11-05
EA201300421A1 (ru)	2013-08-30	Комбинированная терапия для лечения инфекции hcv
WO2020219766A8 (en)	2021-10-28	Compositions useful in treatment of rett syndrome